Corsair Pharma is developing a transdermal patch that delivers an inactive prodrug of treprostinil to provide consistent blood levels for patients with pulmonary arterial hypertension (PAH). This approach eliminates the need for invasive intravenous or subcutaneous administration, reducing pain and improving treatment adherence.
Funding
$23M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NRFounders
Product
Problem
Current treatments for pulmonary arterial hypertension (PAH) using prostacyclin analogs like treprostinil often require continuous intravenous or subcutaneous administration, which can be inconvenient, painful, and lead to adherence issues. Oral and inhaled forms of treprostinil present challenges due to fluctuating blood levels, adverse events, local irritation, and suboptimal clinical use.
Solution
Corsair Pharma is developing a transdermal patch system, TRX-248, designed to deliver a consistent dose of treprostinil for PAH treatment through an inactive prodrug. The patch delivers the prodrug, which is converted to treprostinil in the liver, providing stable blood levels comparable to continuous infusion without the need for invasive procedures. This approach aims to improve patient convenience, reduce infusion site pain and reactions, and offer physicians greater flexibility in mono- and combination therapy.
Target Audience
The primary target audience includes patients with pulmonary arterial hypertension (PAH) and their physicians, specifically those seeking a more convenient and tolerable method of treprostinil administration.
Features
- Proprietary transdermal patch designed for once-daily application
- Delivers an inactive prodrug of treprostinil that converts to the active drug in the liver
- Aims to provide consistent blood levels of treprostinil, comparable to continuous infusion
- Designed to mitigate infusion site pain and reactions associated with current treprostinil formulations
- Completed preclinical program with positive results
- Phase 1 human trial planned to evaluate pharmacokinetics and safety/tolerability